迪奥斯梅丁通过改善肝脏内皮内皮细胞功能障碍来缓解TNFα诱导的肝炎
Dariusz Żurawek1, Natalia Pydyn2, Piotr Major3
1Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Department of General Biochemistry, Gronostajowa 7, Kraków 30-387, Poland; Douglas Mental Health University Institute, McGill University, 6875 LaSalle Boulevard, Montreal, QC H4H 1R3, Canada.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|January 15, 2025
概括
该研究开发了一种肝炎的小鼠模型,并发现黄胺 (flavonoid) 的迪奥斯梅丁通过向肝脏内侧内皮细胞功能障碍来减少肝炎. 这表明diosmetin.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 无菌炎症是肝脏疾病的关键驱动因素,如非酒精性脂肪肝疾病.
- 瘤坏死因子α (TNFα) 激活肝脏内皮细胞 (LSEC),促进肝脏炎症.
- 在患有高TNFα,LSEC功能障碍和肝炎的肥胖患者中观察到Mcpip1表达的减少.
研究的目的:
- 创建和验证LSEC功能障碍的小鼠模型,反映高TNFα的肥胖患者.
- 通过调节LSEC功能障碍来研究迪奥斯梅丁作为治疗肝炎的治疗剂的潜力.
主要方法:
- 在髓状细胞 (Mcpip1fl/flLysMCre) 中生成了Mcpip1淘汰小鼠以模拟患者的炎症.
- 在实验室和体内对小鼠给予迪奥斯梅丁,并评估其对LSEC激活和肝炎的作用.
- 研究了潜在的机制,包括NF-κB通路.
主要成果:
- Mcpip1fl/flLysMCre小鼠表现出与患者观察一致的全身和肝脏炎症.
- 在小鼠模型中,迪奥斯梅丁治疗显著降低了TNFα诱导的LSEC激活和肝炎.
- 迪奥斯梅丁在肝脏中的抗炎作用可以在不影响全身炎症的情况下实现.
结论:
- Mcpip1fl/flLysMCre小鼠模型是研究肝脏抗炎疗法的宝贵工具.
- 迪奥斯梅丁通过调节LSEC功能障碍,在肝脏中表现出显著的抗炎性质.
- 迪奥斯梅丁显示出作为人类肝脏炎症的辅助疗法的潜力.
相关概念视频
Liver Regeneration
3.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114


